SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs large equity offering and stock-funded Elisity acquisition have put dilution, capital allocation, and execution risk at the center of the discussion as shares sell off. Some traders see the deals as building a broader quantum-computing, networking, and security platform, while others doubt the strategy will create value per share and are focused on upcoming results for evidence of progress.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA accelerated approval of a competing treatment for recurrent respiratory papillomatosis has raised concerns about competition for Precigens PAPZIMEOS. Traders debate whether the rivals dosing regimen will draw demand away or whether PAPZIMEOS commercial head start and established market access will help it retain an advantage, while also watching Precigens upcoming earnings.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Attention centers on Alpha Taus oncology pipeline and a packed clinical catalyst calendar, including the FDA-expanded REGAIN glioblastoma study, completed enrollment in its expanded pancreatic cancer trial, and a possible U.S. Keytruda-combination trial. Traders are broadly bullish on the trial progress and upcoming data, though some are waiting for official updates and larger datasets before treating early results as proof.

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

Centrus Energy Corp 

Centrus shares are drawing attention amid a steep selloff, with traders frequently blaming share and warrant issuance and worrying about further dilution. Bulls argue the financing supports the companys domestic uranium-enrichment expansion and point to a reported first centrifuge shipment, while bears question the valuation and how quickly that growth can translate into results.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons strong third-quarter earnings beat is driving attention, with growth in Dupixent and Eylea HD helping offset pressure on legacy Eylea. Traders reacted to the report with a sharp rally and bullish options positioning, while some remain focused on biosimilar competition and the decline in legacy Eylea sales.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarnas prolonged share-price slide after its recent earnings and guidance concernsparticularly weaker German-market expectations and continued investment spendingdominates discussion ahead of the next report. Traders are frustrated by persistent selling, with some blaming shorting or manipulation, while bullish investors view the weakness as a buying opportunity based on partnerships and longer-term growth prospects.

Algorand (ALGO) is a cryptocurrency launched in 2019. Algorand has a current supply of 10,000,000,000 with 9,076,179,334.339727 in circulation. The last known price of Algorand is 0.09376203 USD and is down -1.34 over the last 24 hours. It is currently trading on 586 active market(s) with $49,710,890.79 traded over the last 24 hours. More information can be found at http://algorand.foundation.

Algorand

ALGOs steep long-term decline and weak price action are driving a split between traders calling for further losses and holders arguing that a bottom may be forming ahead of an altcoin recovery. Bulls point to Algorands post-quantum upgrades and potential payments and tokenization use cases, while bears cite limited adoption, token-supply pressure and persistent underperformance.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs Q3 earnings report is the dominant focus, with traders looking beyond a potential beat to guidance and continued U.S. commercial growth. Bulls expect AI demand to support further growth, while bears argue the stocks high valuation leaves little room for merely solid results, especially amid a broader pullback in AI-linked shares.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Mercks quarterly results beat expectations and the company raised its full-year outlook, prompting discussion of Keytruda and Gardasil performance alongside questions about the durability of growth and the coming patent cliff. Traders are also weighing the partnered Moderna melanoma-vaccine results as a potential pipeline opportunity, while debating how broadly the treatment could translate commercially.

TRON (TRX) is a cryptocurrency launched in 2018. TRON has a current supply of 95,023,844,090.614844 with 95,023,861,343.880544 in circulation. The last known price of TRON is 0.3125405 USD and is up 1.67 over the last 24 hours. It is currently trading on 1389 active market(s) with $1,085,916,839.31 traded over the last 24 hours. More information can be found at https://trondao.org/.

Tron

TRON is drawing attention for its relative resilience and gradual recovery after a pullback, with traders discussing bullish chart patterns and a possible continuation of the uptrend. Optimists also cite the networks stablecoin-transfer activity, while skeptics say the token has been rangebound and has yet to deliver meaningful gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
